Cachexia is a complex metabolic multi‐organ syndrome characterized by at least 5% of weight loss, muscle and adipose tissue wasting and inflammation, as it taps into other sources of energy, namely skeletal muscle and adipose tissue when the body senses a lack of nutrition. Cachexia is characterized by increased pro‐inflammatory factors and adversely affects the patients’ ability to fight against infection and withstand treatment by chemotherapy and radiotherapy. It is often associated with an elevated basal metabolic rate, despite a decrease in physical activity and total energy expenditure. Muscle atrophy results from a decrease in protein synthesis, and increase in protein degradation, or a combination of both. This results in a decreased quality of life and reduced survival rates.
Multiple abnormalities in protein, fat, and carbohydrate metabolism as well as peripheral hormone and neuropeptide metabolism have been reported as the cause of cancer cachexia. Investigations in humans suggest a central role of tumor‐induced inflammation as the primary cause of cachexia development.
Get FREE sample copy at:
https://www.delveinsight.com/sample-request/cancer-cachexia-CC-epidemiology-insights
The DelveInsight Cancer Cachexia epidemiology report gives a thorough understanding of the Cancer Cachexia by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Cancer Cachexia in the US, Europe, and Japan.The report covers the detailed information of the Cancer Cachexia epidemiology scenario in seven major countries (US, EU5, and Japan).
Key Highlights Of The Report
As per a Japanese study conducted by Aoyagi et al. “Cancer cachexia, mechanism and treatment”, cachexia occurs in the majority of terminal cancer patients and is responsible for the death of 22% of cancer patients.
Several secondary studies suggest that the overall incidence of cachexia is high and in industrialized countries, such as, North America, Europe, Japan it is growing. It is currently estimated that cachexia affects approximately 9 million patients, which is about 1% of all patients with any disease.
It is estimated that more than 30% of cancer patients die due to cachexia, and more than 50% of patients die with cachexia being present.
Among late stage patients, cachexia affects 50– 80% of cancer patients.
-
Delveinsight’s Cancer Cachexia epidemiology division provides insights about historical and current patient pool and forecasted trends for every seven major countries.
-
The Cancer Cachexia epidemiology data are studied through all possible divisions to give a better understanding of the Disease scenario in 7MM.
-
The Cancer Cachexia epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030.
-
It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
According to the Cancer Cachexia Hub, approximately half of all patients with cancer experience cachexia. This rate of occurrence rises to as high as 86% in the last 1–2 weeks of life, and with 45% of patients losing more than 10% of their original body weight over disease progression.
Scope of the Report
-
The report provides insight into the historical and forecasted patient pool of Cancer Cachexia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
-
The report assesses the disease risk and burden and highlights the unmet needs of Cancer Cachexia.
-
The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
-
The Cancer Cachexia report provides a detailed overview explaining Cancer Cachexia causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns.
-
The Cancer Cachexia Epidemiology Report and Model provide an overview of the risk factors and global trends of Cancer Cachexia in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan).
-
The report provides the segmentation of the Cancer Cachexia epidemiology.
Key Benefit of Cancer Cachexia Epidemiology Report
The Cancer Cachexia Epidemiology report will allow the user to –
-
Develop business strategies by understanding the trends shaping and driving the global Cancer Cachexia market
-
Quantify patient populations in the global Cancer Cachexia market to improve product design, pricing, and launch plans
-
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Cancer Cachexia therapeutics in each of the markets covered
-
Understand the magnitude of Cancer Cachexia population by its epidemiology
-
The Cancer Cachexia Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources
Table of Contents
-
Key Insights
-
Executive Summary of Cancer Cachexia
-
Cancer Cachexia Disease Background and Overview
-
Cancer Cachexia Patient Journey
-
Cancer Cachexia Epidemiology and Patient Population
-
Cancer Cachexia Treatment Algorithm, Current Treatment, and Medical Practices
-
KOL Views on Cancer Cachexia
-
Cancer Cachexia Unmet Needs
-
Appendix
-
DelveInsight Capabilities
-
Disclaimer
*The table of contents is not exhaustive; will be provided in the final report
Related Reports
Cancer Cachexia (CC) Market Insights, Epidemiology, and Market Forecast—2030
DelveInsight’s ‘Cancer Cachexia (CC) – Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the Cancer Cachexia (CC), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Cancer Cachexia Pipeline Insights, 2020
Cancer Cachexia Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Cancer Cachexia market.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/